Abstracts tagged "Auto-immunity"

Abstract Number: 2453 • 2012 ACR/ARHP Annual Meeting
The Role of Bob1 in Rheumatoid Arthritis: Potential Implications for Autoimmunity
Nataliya Yeremenko¹, Tineke Cantaert¹, Melissa N. van Tok², Ioana Gofita¹, Juan D. Canete³, Paul P. Tak⁴, Hergen Spits⁵ and Dominique L. Baeten⁴, ¹Division of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ²Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ³Arthritis Unit. Rheumatology Department, Hospital Clínic, Barcelona, Spain, ⁴Division of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Division of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ⁵Tytgat Institute for Liver and Intestinal Research, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is a prototypic autoimmune disease characterized by a prominent humoral autoimmunity. Of particular relevance is the local production of autoantibodies such…
Abstract Number: 2345 • 2012 ACR/ARHP Annual Meeting
HRES-1/RAB4-Mediated Loss of DRP1 Inhibits Mitophagy, Promotes Accumulation of Mitochondria and Serves As Target for Treatment in SLE
Tiffany Telarico¹, David Fernandez¹, Zachary A. Oaks², Gergely Talaber³, Mark Haas⁴, Michael P. Madaio⁵ and Andras Perl⁶, ¹Medicine, SUNY Upstate Medical University, Syracuse, NY, ²SUNY, Syracuse, NY, ³Medicine, SUNY, Syracuse, NY, ⁴Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Medical College of Georgia, Augusta, GA, ⁶Dept of Medicine, SUNY Upstate Medical University, Syracuse, NY
Background/Purpose: T cells from patients with systemic lupus erythematosus (SLE) exhibit accumulation of mitochondria and activation of the mammalian target of rapamycin (mTOR). Although mTOR…
Abstract Number: 2326 • 2012 ACR/ARHP Annual Meeting
Discovery of a Highly Potent, Selective Reversible Covalent Inhibitor of JAK3 Kinase
Ronald J. Hill¹, Angelina Bisconte¹, J. Michael Bradshaw¹, Ken Brameld², Eun Ok Kim¹, Xiaoyan Li², Tim Owens², Erik Verner² and David M. Goldstein², ¹Biology, Principia Biopharma, South San Francisco, CA, ²Chemistry, Principia Biopharma
Background/Purpose: Targeting of the JAK-STAT pathway has been shown to be efficacious for treatment of patients with rheumatoid arthritis through the successful use of pan-JAK…
Abstract Number: 1699 • 2012 ACR/ARHP Annual Meeting
Neutropenia After Rituximab in Rheumatoid Arthritis and Other Autoimmune Diseases Is a Rare Events : Date From the Autoimmunity and Rituximab Registry
Jean Hugues Salmon¹, Patrice Cacoub², Bernard G. Combe³, Jean Sibilia⁴, Beatrice Pallot Prades⁵, Olivier Fain⁶, Alain G. Cantagrel⁷, Maxime Dougados⁸, Olivier Meyer⁹, Philippe Carli¹⁰, Edouard Pertuiset¹¹, Isabelle Pane¹², Philippe Ravaud¹³, Xavier Mariette¹⁴ and Jacques-Eric Gottenberg¹⁵, ¹Rheumatology, Reims, France, ²Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ³Rhumatologie, Hopital Lapeyronie, Montpellier, France, ⁴Rheumatology, CHU Hautepierre, Strasbourg, France, ⁵Rheumatology department, Saint Etienne university hospital, Saint Etienne, France, ⁶Internal Medicine, Jean Verdier Hospital, Bondy, France, ⁷Rheumatology, Place du Docteur Baylac, Toulouse, France, ⁸Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ⁹Rheumatology, Hopital Bichat, Paris, France, ¹⁰HIA sainte Anne, Toulon, France, ¹¹Rheumatology, Ch Rene Dubos, Pontoise, France, ¹²Hotel Dieu University Hospital Paris, Hotel Dieu University Hospital Paris, Paris, France, ¹³Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ¹⁴Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, ¹⁵Rheumatology, Strasbourg University Hospital, Strasbourg, France
Background/Purpose: Limited data are available regarding the proportion and severity of late onset neutropenia after RTX in large and unselected populations of patients with various…
Abstract Number: 1672 • 2012 ACR/ARHP Annual Meeting
Myosin Skews Effector Immune Cells of Scurfy Mice to Target Muscles in an Adoptive Transfer Model of Myositis
Nicholas Young¹, Rahul Sharma², Alexandra Friedman³, Benjamin Kaffenberger¹ and Wael N. Jarjour⁴, ¹Immunology and Rheumatology, The Ohio State University Medical Center, Columbus, OH, ²Medicine, University of Virginia Health System, Charlottesville, VA, ³Immunology and Rheumatology, The Ohio State University Wexner Medical Center, Columbus, OH, ⁴Dept of Rheumatology/Medicine, The Ohio State University Wexner Medical Center, Columbus, OH
Background/Purpose: Myositis is associated with an inflammatory process that results in pronounced muscle weakness and is observed in some regulatory T cell (Treg) deficient mouse…
Abstract Number: 1649 • 2012 ACR/ARHP Annual Meeting
French Cohort Study of 141 Cases of Autoimmune Congenital Heart Block
Kateri Levesque¹, Alice Maltret², Mohamed Hamidou³, Moez Jallouli⁴, Jean Loup Pennaforte⁵, Pauline Orquevaux⁵, Jean-Charles Piette⁶, Zahir Amoura⁴, Francois Barriere⁷, Jérome Le Bidois², Laurent Fermont², Laurence Cohen⁸, Olivier Meyer⁹, Olivier Fain¹⁰, Arnaud Theulin¹¹, Hugues Lucron¹², Francois Sassolas¹³, Holly Bezanahary¹⁴, Gaëlle Guettrot-Imbert¹⁵, Pascal Seve¹⁶, Elizabeth Diot¹⁷, Nathalie Morel¹, Christophe Deligny¹⁸, Elisabeth Villain² and Nathalie Costedoat-Chalumeau¹⁹, ¹Internal Medicine, Groupe Hospitalier Pitié-Salpétrière, Paris, France, ²Cardiology, Groupe Hospitalier Necker - Enfants Malades, Paris, France, ³Internal Medicine Department, Nantes University Hospital, Nantes, France, ⁴Department of Internal Medicine 2. Referal center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France, ⁵Hu Robert Debre, CHU Reims, Reims, France, ⁶Hospital Pitie, Paris, ⁷Pediatry, CHU Nantes, Nantes, France, ⁸Cardiology, Institut Jacques Cartier, ⁹Rheumatology, Hopital Bichat, Paris, France, ¹⁰Internal Medicine, Service de médecine interne, Université Paris 13, AP-HP, Hôpital Jean Verdier, Bondy, France, ¹¹Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹²Cardiology, CHU Fort-de-France, Fort de France, Martinique, ¹³Cardiology, CHU Lyon, Lyon, France, ¹⁴Internal Medicine, University Hospital of Limoges, Limoges, France, ¹⁵Internal Medicine, Hopital Gabriel Montpied, Clermont-Ferrand, France, ¹⁶Internal medicine, CHU Lyon, Lyon, France, ¹⁷Department of Internal Medicine, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire de Tours, Tours, France, Tours, France, ¹⁸Rhumatologie Et Médecine Interne, Centre hospitalier Universitaire de Fort de France, Fort de France, Martinique, ¹⁹Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France
Background/Purpose: Cardiac neonatal lupus manifestations mainly include congenital heart block (CHB), endocardial fibroelastosis and dilated cardiomyopathy. We report the preliminary results of the French registry…
Abstract Number: 1072 • 2012 ACR/ARHP Annual Meeting
Enzymatic Lipid Oxidation Contributes to the Maintenance of Self-Tolerance by Regulating Antigen Clearance and Dendritic Cell Function
Stefan Uderhardt¹, Tobias Rothe¹, Elisabeth Zinser², Olga Oskolkova³, Martin Herrmann⁴, Alexander Steinkasserer⁵, Valery Bochkov³, Georg Schett⁶ and Gerhard Kronke¹, ¹Internal Medicine 3, University of Erlangen, Erlangen, Germany, ²University of Erlangen, Erlangen, Germany, ³Department of Vascular Biology and Thrombosis Research, Center for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria, Vienna, Austria, ⁴Instiute for Immunology, PhD, Erlangen, Germany, ⁵Department of Immune Modulation at the Department of Dermatology, University Hospital Erlangen, Erlangen, Germany, ⁶Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: During inflammation and tissue damage, pathogens as well as dying cells are ingested by different phagocytes such as macrophages and dendritic cells. The uptake…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].